The British drug-maker, AstraZeneca signed an exclusive deal with Beijing based Shenzhen Kangtai Biological Products Co., Ltd to manufacture a potential COVID-19 vaccine in mainland China.
The British drug-maker, AstraZeneca signed an exclusive deal with Beijing based Shenzhen Kangtai Biological Products Co., Ltd to manufacture a potential COVID-19 vaccine in mainland China.